echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 4+7 Expanded Varieties "The Arrow is on the String" These popular varieties of over-reviews are ready to go!

    4+7 Expanded Varieties "The Arrow is on the String" These popular varieties of over-reviews are ready to go!

    • Last Update: 2019-10-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Sina pharmaceutical previously understood that the next round of 4 + 7 volume procurement is planned to expand varieties, which is expected to be launched at the end of this year However, on October 23, a "4 + 7" meeting minutes flowed out of the network, which revealed that the next volume purchase will be started in April and may next year, and the specific varieties depend on the passing of consistency evaluation varieties (online 4 + 7 latest meeting minutes source: EMBA in pharmaceutical industry) According to the minutes of the meeting, a new round of belt purchase will be carried out in 2020 In addition to the nationwide implementation of belt purchase for 25 varieties this year, more varieties will be included in the scope of belt purchase If according to the requirements of this meeting minutes, the next round of 4 + 7 belt purchase depends on the passing of consistency evaluation varieties So, it is very likely that the over evaluated hot varieties will become the next round of centralized purchase target Not long ago, yaozhi.com published the top 10 "over evaluated" popular varieties of consistency evaluation, which are rosuvastatin tablets, amlodipine besylate tablets, cefuroxime axetil tablets, tenofovir dipivoxil fumarate tablets, glimepiride tablets, metformin hydrochloride tablets, metformin hydrochloride sustained-release tablets, montmorillonite powder, atorvastatin calcium tablets, Cefalexin Capsules (see previous articles of sina pharmaceutical:) The picture comes from the intelligence of medicine data If not included in the first round of collection, metformin hydrochloride tablets, glimepiride tablets and Cefalexin Capsules are likely to be the next round of collection targets In addition, amlodipine besylate tablets, metformin hydrochloride tablets, Amoxicillin Capsules, montmorillonite powder, ranitidine hydrochloride capsules, paracetamol tablets, indapamide tablets, captopril tablets, Cefalexin Capsules, metronidazole tablets, etc account for the top ten in the number of enterprises applying for varieties From the perspective of 4 + 7 expansion, for the varieties that have been evaluated more than 3, the overall decline of the enterprise is 23% on average, and the average decline of competition over 3 is 40% Throughout the industry situation, there is no market through consistency evaluation Under the 4 + 7 price depression, how to fill the R & D cost through price game is the core issue that enterprises should consider at present And it's important to have the first or previous reviews At the end of December last year, the State Food and Drug Administration issued the latest time limit requirements for consistency evaluation It announced that "for generic drugs including basic drug varieties approved for listing before the implementation of new registration and classification of chemical drugs, after the first variety passed the consistency evaluation, other pharmaceutical production enterprises should complete the consistency evaluation of the same variety within three years in principle If the enterprise fails to complete the evaluation within the time limit, it may apply to the local provincial drug regulatory department for an extension of evaluation if it is deemed to be clinically necessary and in short supply in the market After the provincial drug regulatory department and the health administrative department organize the research and confirmation, the enterprise may extend the evaluation appropriately If it is not completed within the time limit, it shall not be re registered " Basically, in the current industry situation, pharmaceutical companies need to adjust their own strategies and select varieties reasonably On the one hand, it is better to occupy market share of no or few evaluated varieties first; on the other hand, if the market share of varieties is small and there are many competitors, there is no need to make consistency evaluation, and it can be considered to change production and stop production The first round of 4 + 7 will come to an end, and the second round of 4 + 7 expansion is expected to be implemented at the end of this year and early next year 4 + 7 accelerated the reshuffle of the generic pharmaceutical industry Many industry figures show that in the future, the advantages of the head enterprises will obviously win, or new super giants will appear Small generic companies will be merged and eliminated According to the data of yaozhi.com, the top ten enterprises that have passed the consistency evaluation are Qilu pharmaceutical, Zhengda Tianqing, Zhejiang Huahai, Sichuan Kelun, Shiyao Ouyi, Jiangsu Haosen, Jiangsu Hengrui, Shenzhen xinlitai, Chongqing Yaoyou and Zhejiang Jingxin The picture comes from the intelligence of medicine data It is worth mentioning that in the top three, Qilu pharmaceutical declared 30 varieties and passed 13 varieties; Zhengda Tianqing declared 20 varieties and passed 11; Zhejiang Huahai declared 18 varieties and passed 11 According to statistics, about 90% of China's 5000 pharmaceutical enterprises are generic pharmaceutical enterprises, and the generic pharmaceutical industry has long been in a "small, disorderly and scattered" situation Driven by 4 + 7, medical insurance control fees and other factors, there will be no unexpected increase in the shuffling of the generic pharmaceutical market, the whole industry will have merger and reorganization, realize resource integration, etc., and high-quality varieties will get more market space If according to the industry speculation, it is obvious that in the future, these enterprises with a large number of over evaluated varieties will become the winners after shuffling According to the minutes of the meeting, the first round of centralized purchase of amlodipine besylate from Zhongjing won the bid at 0.15 yuan per tablet However, as the raw material is not self-produced, the raw material manufacturer will raise the price just after winning the bid In contrast, the raw material manufacturers have obvious advantages in this respect.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.